Audentes Therapeutics (NASDAQ:BOLD) received a $37.00 price target from equities research analysts at HC Wainwright in a research note issued on Thursday, January 4th. The firm presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price objective suggests a potential downside of 2.73% from the stock’s current price.
A number of other research analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, November 17th. BidaskClub lowered shares of Audentes Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 6th. Bank of America reaffirmed a “buy” rating and set a $33.00 price objective (up previously from $23.00) on shares of Audentes Therapeutics in a research report on Friday, September 22nd. Leerink Swann reaffirmed an “outperform” rating and set a $29.00 price objective (up previously from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. Finally, Raymond James Financial initiated coverage on shares of Audentes Therapeutics in a research report on Thursday, October 12th. They set a “market perform” rating for the company. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $35.00.
Audentes Therapeutics (NASDAQ BOLD) traded down $0.49 during trading on Thursday, reaching $38.04. 966,142 shares of the company’s stock were exchanged, compared to its average volume of 564,552. The firm has a market cap of $1,367.19, a price-to-earnings ratio of -10.90 and a beta of -0.21. Audentes Therapeutics has a 52-week low of $13.90 and a 52-week high of $41.80.
Audentes Therapeutics (NASDAQ:BOLD) last released its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.88). research analysts predict that Audentes Therapeutics will post -3.49 earnings per share for the current year.
In other news, Director Louis G. Lange sold 18,000 shares of the company’s stock in a transaction dated Friday, December 22nd. The shares were sold at an average price of $30.88, for a total transaction of $555,840.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Suyash Prasad sold 8,000 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. Insiders have sold 36,000 shares of company stock valued at $1,052,480 in the last ninety days. 47.30% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of BOLD. Redmile Group LLC increased its stake in Audentes Therapeutics by 77.8% in the second quarter. Redmile Group LLC now owns 1,459,616 shares of the biotechnology company’s stock valued at $27,922,000 after acquiring an additional 638,780 shares during the period. Vanguard Group Inc. increased its stake in Audentes Therapeutics by 130.3% in the second quarter. Vanguard Group Inc. now owns 678,412 shares of the biotechnology company’s stock valued at $12,978,000 after acquiring an additional 383,837 shares during the period. Artal Group S.A. bought a new stake in Audentes Therapeutics in the third quarter valued at about $5,602,000. State Street Corp increased its stake in Audentes Therapeutics by 231.6% in the second quarter. State Street Corp now owns 221,276 shares of the biotechnology company’s stock valued at $4,234,000 after acquiring an additional 154,544 shares during the period. Finally, Alliancebernstein L.P. increased its stake in Audentes Therapeutics by 31.5% in the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock valued at $12,256,000 after acquiring an additional 153,617 shares during the period. 78.95% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/28/audentes-therapeutics-bold-given-a-37-00-price-target-by-hc-wainwright-analysts.html.
About Audentes Therapeutics
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.